How to buy Can-Fite BioPharma stock

Can-Fite BioPharma Ltd is a biotechnology business based in the US. Can-Fite BioPharma shares (CANF) are listed on the NYSE MKT and all prices are listed in US Dollars. Can-Fite BioPharma employs 8 staff and has a trailing 12-month revenue of around USD$805,000.

How to buy shares in Can-Fite BioPharma

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Can-Fite BioPharma. Find the stock by name or ticker symbol: CANF. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Can-Fite BioPharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Can-Fite BioPharma, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Can-Fite BioPharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Can-Fite BioPharma share price

Use our graph to track the performance of CANF stocks over time.

Can-Fite BioPharma shares at a glance

• Key figures

Information last updated 2021-03-18.

52-week range	USD$1.15 - USD$3.0657
50-day moving average	USD$2.1951
200-day moving average	USD$1.9307
Wall St. target price	USD$5
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-5.01

Buy Can-Fite BioPharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Can-Fite BioPharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Can-Fite BioPharma Ltd by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Can-Fite BioPharma financials

Revenue TTM	USD$805,000
Gross profit TTM	USD$2 million
Return on assets TTM	-75.73%
Return on equity TTM	-151.3%
Profit margin	0%
Book value	$0.63
Market capitalisation	USD$45.9 million

TTM: trailing 12 months

Shorting Can-Fite BioPharma shares

There are currently 335,651 Can-Fite BioPharma shares held short by investors – that's known as Can-Fite BioPharma's "short interest". This figure is 2.5% down from 344,092 last month.

There are a few different ways that this level of interest in shorting Can-Fite BioPharma shares can be evaluated.

Can-Fite BioPharma's "short interest ratio" (SIR)

Can-Fite BioPharma's "short interest ratio" (SIR) is the quantity of Can-Fite BioPharma shares currently shorted divided by the average quantity of Can-Fite BioPharma shares traded daily (recently around 2.0 million). Can-Fite BioPharma's SIR currently stands at 0.17. In other words for every 100,000 Can-Fite BioPharma shares traded daily on the market, roughly 170 shares are currently held short.

However Can-Fite BioPharma's short interest can also be evaluated against the total number of Can-Fite BioPharma shares, or, against the total number of tradable Can-Fite BioPharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Can-Fite BioPharma's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Can-Fite BioPharma shares in existence, roughly 20 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Can-Fite BioPharma shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Can-Fite BioPharma.

Find out more about how you can short Can-Fite BioPharma stock.

Can-Fite BioPharma share dividends

We're not expecting Can-Fite BioPharma to pay a dividend over the next 12 months.

Have Can-Fite BioPharma's shares ever split?

Can-Fite BioPharma's shares were split on a 1:15 basis on 9 May 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Can-Fite BioPharma shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Can-Fite BioPharma shares which in turn could have impacted Can-Fite BioPharma's share price.

Can-Fite BioPharma share price volatility

Over the last 12 months, Can-Fite BioPharma's shares have ranged in value from as little as $1.15 up to $3.0657. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Can-Fite BioPharma's is 1.6062. This would suggest that Can-Fite BioPharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Can-Fite BioPharma overview

Can-Fite BioPharma Ltd. , a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd.

Frequently asked questions

• What percentage of Can-Fite BioPharma is owned by insiders or institutions?

  Currently 1.188% of Can-Fite BioPharma shares are held by insiders and 6.519% by institutions.

• How many people work for Can-Fite BioPharma?

  Latest data suggests 8 work at Can-Fite BioPharma.

• When does the fiscal year end for Can-Fite BioPharma?

  Can-Fite BioPharma's fiscal year ends in December.

• Where is Can-Fite BioPharma based?

  Can-Fite BioPharma's address is: 10 Bareket Street, Petah Tikva, Israel, 49170

• What is Can-Fite BioPharma's ISIN number?

  Can-Fite BioPharma's international securities identification number is: US13471N2018

• What is Can-Fite BioPharma's CUSIP number?

  Can-Fite BioPharma's Committee on Uniform Securities Identification Procedures number is: 13471N102